Tounjian Advisory Partners LLC Invests $1.28 Million in Pfizer Inc. (NYSE:PFE)

Tounjian Advisory Partners LLC bought a new stake in Pfizer Inc. (NYSE:PFE) during the first quarter, according to its most recent disclosure with the SEC. The institutional investor bought 50,552 shares of the biopharmaceutical company’s stock, valued at approximately $1,281,000.

Several other hedge funds have also bought and sold shares of the company. Vanguard Group Inc. lifted its position in shares of Pfizer by 0.4% in the fourth quarter. Vanguard Group Inc. now owns 518,535,151 shares of the biopharmaceutical company’s stock valued at $13,756,738,000 after buying an additional 2,285,276 shares during the last quarter. Charles Schwab Investment Management Inc. raised its stake in Pfizer by 19.5% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 155,459,101 shares of the biopharmaceutical company’s stock valued at $4,124,330,000 after acquiring an additional 25,315,159 shares during the period. Geode Capital Management LLC lifted its holdings in Pfizer by 2.5% during the 4th quarter. Geode Capital Management LLC now owns 120,589,782 shares of the biopharmaceutical company’s stock valued at $3,190,131,000 after purchasing an additional 2,923,537 shares during the last quarter. Norges Bank acquired a new position in shares of Pfizer in the fourth quarter valued at $2,328,986,000. Finally, Massachusetts Financial Services Co. MA raised its position in shares of Pfizer by 7.5% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 76,502,238 shares of the biopharmaceutical company’s stock valued at $2,029,604,000 after purchasing an additional 5,350,381 shares during the period. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Stock Up 1.0%

NYSE PFE opened at $23.36 on Monday. The business has a fifty day moving average price of $22.95 and a two-hundred day moving average price of $25.00. The stock has a market capitalization of $132.81 billion, a PE ratio of 16.57, a PEG ratio of 0.64 and a beta of 0.57. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $31.54. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, topping the consensus estimate of $0.67 by $0.25. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business had revenue of $13.72 billion during the quarter, compared to the consensus estimate of $14.43 billion. During the same period in the prior year, the company earned $0.82 EPS. Pfizer’s revenue for the quarter was down 7.8% on a year-over-year basis. Equities analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 13th. Investors of record on Friday, May 9th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 7.36%. The ex-dividend date of this dividend is Friday, May 9th. Pfizer’s dividend payout ratio is 124.64%.

Analysts Set New Price Targets

Several analysts recently commented on the stock. Guggenheim reaffirmed a “buy” rating on shares of Pfizer in a report on Tuesday, March 18th. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $25.00 target price (down previously from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. UBS Group increased their target price on Pfizer from $24.00 to $25.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 30th. Cantor Fitzgerald assumed coverage on Pfizer in a research note on Tuesday, April 22nd. They issued a “neutral” rating and a $24.00 price target for the company. Finally, Hsbc Global Res raised Pfizer to a “strong-buy” rating in a report on Monday, March 10th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, four have given a buy rating and three have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Pfizer has a consensus rating of “Moderate Buy” and an average target price of $29.17.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.